Discontinuation of the Clinical Development of Fusion Inhibitor T-1249
Discontinuation of the Clinical Development of Fusion Inhibitor T-1249
Luz Martín-Carbonero
NULL
*Correspondence: Luz Martín-Carbonero, Email not available
Abstract
In a surprise move that signals a significantsetback in second-generation fusion inhibitor drugdevelopment, Roche and Trimeris announced onJanuary 2004 that they have halted, and put on indefinitehold, further clinical development of theexperimental HIV fusion inhibitor T-1249.
